Summary & Overview
HCPCS C9157: Injection, tofersen, 1 mg
HCPCS Level II code C9157 denotes the administration of tofersen, billed as an injection per 1 mg unit. Tofersen is a targeted therapeutic agent; capturing its administration at the milligram level enables precise billing for high-cost specialty drugs and supports accurate utilization tracking. Nationally, drug-specific HCPCS Level II codes like C9157 are important for payer coverage decisions, claims adjudication, and monitoring of specialty medication use.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code's clinical context and service setting, typical payer considerations, and the types of benchmarks and policy topics relevant to specialty injectable therapies. The publication also outlines common modifier usage and payer-specific billing nuances where available. Where input data is incomplete, the report notes that specific payer policies, associated taxonomies, and ICD-10 pairings are not provided.
This summary is intended for billing managers, revenue cycle professionals, and policy analysts seeking a national view of how a drug-specific HCPCS Level II code functions within specialty drug billing and payer workflows.
Billing Code Overview
HCPCS Level II code C9157 represents Injection, tofersen, 1 mg. This code describes the administration of the medication tofersen, billed per milligram, and is classified as a drug injection service. The service type is an injectable pharmaceutical drug administration. The typical site of service for billing this administration is an outpatient infusion or injection setting, such as a clinic, ambulatory infusion center, or hospital outpatient department.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with confirmed genetic motor neuron disease due to a pathogenic SOD1 gene variant presenting for disease-modifying therapy. The patient is evaluated by a neuromuscular specialist in an outpatient infusion clinic or hospital outpatient infusion center. After baseline neurologic assessment, respiratory function testing (spirometry or SNIP), and laboratory evaluation, the provider orders C9157 — injection, tofersen, 1 mg. The medication is prepared by pharmacy under sterile conditions and administered as an intrathecal or intramuscular/intravenous formulation per product labeling and site protocol (note: administration route depends on current prescribing information). The clinical workflow includes pre-infusion nursing assessment, verification of informed consent and prior authorization, medication reconciliation, administration by an RN or infusion nurse, monitoring for adverse reactions during and after dosing, documentation of lot number and dose, and scheduling of follow-up neurologic and safety labs. Typical sites of service are outpatient infusion centers, hospital outpatient departments, or specialty clinics with capabilities for biologic administration and post-dose monitoring.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required to prepare/coordinate or administer the biologic is substantially greater than typical (rare for standard infusions). |